Fulcrum stumbles in PhII of old GSK drug, sending shares tumbling
Investors are selling off shares of Fulcrum Therapeutics $FULC after their lead drug failed in a Phase II trial.
The company, founded three years ago on new research techniques such as CRISPR screening, isolated a gene called DUX4 they believed to have a central role in facioscapulohumeral muscular dystrophy, where patients’ muscle dies and is replaced by fat. And to target it, they licensed a GlaxoSmithKline drug that had failed as a cardio drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.